Pictilisib

Pictilisib Basic information
Product Name:Pictilisib
Synonyms:Pictilisib;Thieno[3,2-d]pyrimidine, 2-(1H-indazol-4-yl)-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-(4-morpholinyl)-;GDC-0941;GDC-0941 free base;2-(1H-Indazol-4-yl)-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-(4-morpholinyl)thieno[3,2-d]pyrimidine;GDC-0941 bismesylate;2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine;4-(2-(1H-Indazol-4-yl)-6-((4-(Methylsulfonyl)piperazin-1-yl)Methyl)thieno[3,2-d]
CAS:957054-30-7
MF:C23H27N7O3S2
MW:513.64
EINECS:1312995-182-4
Product Categories:An inhibitor of class I PI3 kinase (PI3K).;Inhibitors;Akt;mTOR;PI3K
Mol File:957054-30-7.mol
Pictilisib Structure
Pictilisib Chemical Properties
Melting point >200oC (dec.)
density 1.53±0.1 g/cm3(Predicted)
storage temp. -20°C
solubility Soluble in DMSO (>25 mg/ml)
form White powder solid.
pka12.22±0.40(Predicted)
color White/off-white
Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
Safety Information
HS Code 29350090
MSDS Information
Pictilisib Usage And Synthesis
DescriptionGDC-0941/Pictilisib (957054-30-7) is a potent and selective inhibitor of class I phosphatidylinositol-3-kinases (PI3K) with significant antitumor activity – IC50’s: PI3Kα = 3nM, PI3Kβ = 33 nM, PI3Kδ = 3 nM, PI3Kγ = 75 nM.1,2?? GDC-0941 is the chemical probe of choice for the pan-inhibition of class I PI3K’s.3?Currently in clinical trials.4
UsesGDC-0941 is a potent and selective oral inhibitor of the class I PI3K. GDC-0941 demonstrated broad spectrum of activity in breast, ovarian, lung, and prostate cancer models. Studies has also shown GDC -0941 may enhance anti-tumor activity of Docetaxel (D494420) in human breast cancer models.
UsesGDC-0941 is a potent and selective oral inhibitor of the class I PI3K. GDC-0941 demonstrated broad spectrum of activity in breast, ovarian, lung, and prostate cancer models. Studies has also shown GDC-0941 may enhance anti-tumor activity of Docetaxel (D494420) in human breast cancer models. Potent PI3K inhibitor.
DefinitionChEBI: A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring.
targetPI3Kα
References1) Folkes?et al.?(2008),?The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine(GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer;? J.?Med. Chem.,?51?5522 2) Raynaud?et al. (2009),?Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinase: from PI-103 through PI-540, PI620 to the oral agent GDC-0941; Mol. Cancer Ther.,?8?1725 3) Knapp et al. (2013),?A public-private partnership to unlock the untargeted kinome; Nat. Chem. Biol.,?9?3 4) Sarker?et al. (2015),?First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors; Clin. Cancer Res.,?21?77
Pictilisib Preparation Products And Raw materials
Motesanib BEZ235 (NVP-BEZ235, Dactolisib) 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-2-CARBOXYLIC ACID PLX4032 2-[(6-Amino-9H-purin-9-yl)methyl]-5-methyl-3-(2-methylphenyl)-4(3H)-quinazolinone ERK Inhibitor N-[4-[5-(1,3-BENZODIOXOL-5-YL)-3-METHOXY-1H-1,2,4-TRIAZOL-1-YL]PHENYL]-2-(PHENYLTHIO)ACETAMIDE Trametinib CAL-101 Compound 23 JNJ-10198409 DL-Malic acid GSK-3β Inhibitor XVIII MIF Antagonist, ISO-1 NSC697923 NSC 23766 TETRAHYDROCHLORIDE MK-2206 2HCl Everolimus

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.